Novo Nordisk’s bispecific antibody Mim8 prevented bleeding events and caused no adverse safety events in the Phase III ...

Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/19.CcrFU5Zy.js ...

Aims Clopidogrel is the most commonly prescribed thienopyridine as part of dual anti-platelet therapy for the treatment of ...

A systematic review and meta-analysis of five studies suggested that patients on GLP-1 receptor agonists were more likely to ...

CSL Behring's gene therapy Hemgenix four years post-infusion data continue to show sustained efficacy and safety in adults with haemophilia B: King of Prussia, Pennsylvania Monday ...

As December 2022 closed out, Pfizer announced positive top-line results from its phase 3 BENEGENE-2 study ... and a high-activity human coagulation FIX gene. The purpose of this gene therapy ...

Harbour BioMed (HKEX: 02142, the "Company"), a global biopharmaceutical company committed to the discovery, development and commercialization of novel antibody therapeutics focusing on immune-oncology ...

Anderson and colleagues are testing these two approaches in a phase 2 study, incorporating a cold air chiller device to make treatment painless, “which is going really well,” he said.

This way, they can start producing coagulation proteins ... research because it’s still finishing its lead optimization phase. But MGX believes it can go ahead with its IND filing by 2026.

Q4 2024 Earnings Call Transcript February 4, 2025 Operator: Hello, and welcome to Regeneron Pharmaceuticals Fourth Quarter ...

Central University Hospital announced on the 10th that it has introduced a state-of-the-art linear accelerator that can ...

The strong magnetic stirrer guarantees homogeneous mixing within the vessel and prevents coagulation ... in boiling during the rapid cool down phase, allowing an extraordinary fast and gentle ...